The Medicines Company (NASDAQ:MDCO) Files An 8-K Other Events

ME Staff 8-k
-
0

The Medicines Company (NASDAQ:MDCO) Files An 8-K Other Events
Item 8.01. Other Events

On March 17, 2017, The Medicines Company (the “Company”) issued a press release reporting results from the ORION-1 phase 2 study of inclisiran, its PCSK9 synthesis inhibitor. The Company also presented data from the ORION-1 phase 2 study at a Late-Breaking Clinical Trials session at American College of Cardiology’s 66th Annual Scientific Session.  A copy of the press release issued by the Company on March 17, 2017, and a copy of the Company’s presentation made on March 17, 2017, are attached hereto as Exhibits 99.1 and 99.2, respectively.

Item 9.01. Exhibits

(d) Exhibits

The following exhibits relating to Item 8.01 shall be deemed to be furnished, and not filed:

99.1 Press release dated March 17, 2017

99.2 Presentation dated March 17, 2017


About The Medicines Company (NASDAQ:MDCO)

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company’s products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.

The Medicines Company (NASDAQ:MDCO) Recent Trading Information

The Medicines Company (NASDAQ:MDCO) closed its last trading session down -4.20 at 48.38 with 20,499,700 shares trading hands.